Stem Cell Therapy Becomes Law in Texas
LA JOLLA, Calif., June 13, 2017 /PRNewswire/ -- House Bill (HB 810) on stem cell therapy has passed in the Texas state legislature and become law. Patients in Texas will now have access to this "Right to Try" innovative form of therapy for those suffering with debilitating and incurable illnesses.
Rita Alexander, Chief Administrative Officer at StemGenex Medical Group in La Jolla, CA, applauded Texas for this landmark legislation and Republican State Rep. Drew Springer, R-Muenster, who strongly advocated for this bill. She noted that over the past three years, "Right to Try" advocates in 33 states have helped enact legislation to eliminate obstacles for terminally ill patients seeking treatments that may not be approved by the Food and Drug Administration (FDA). Those advocates are showing considerable momentum in the remaining 17 states, potentially expediting clinical therapies for patients who have limited options.
"At StemGenex, we are committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells," said Alexander. "Specifically, we use adipose-derived adult stem cell therapy for patients battling conditions such as Multiple Sclerosis, Parkinson's disease, COPD, Rheumatoid Arthritis and Osteoarthritis. We are also committed to the science of stem cell therapy and sponsor five clinical outcome studies registered with the National Institute of Health (NIH) for these diseases."
"What I personally witnessed before the start of StemGenex were patients who had exhausted conventional medical treatments but wanted to try alternative therapies. I was one of them, suffering from severe Rheumatoid Arthritis. I had only three options; I could seek a clinical trial, travel to outside of the U.S. to try alternative therapies such as stem cell treatment or petition the FDA for access to drugs under the agency's "expanded access," or "compassionate use" program. Now, new state laws like the one just passed in Texas, built on model legislation from the Goldwater Institute in Arizona, will allow doctors and patients to make their own informed decisions on treatments that have cleared the safety phase of FDA testing."
Last year, in a move that was seen by some as a response to "Right to Try" laws, the 21(st) Century Cures Act, a landmark piece of legislation focused on medical innovation and medical research, was signed into law by President Obama. This Act provides the FDA with the flexibility to accelerate how it evaluates regenerative medicine treatments, such as stem cell therapies, while maintaining its high standards of safety and efficacy.
"We're on the cusp of a major change on how patients can access stem cell therapy," said Alexander. "Today, new treatments and advances in research are giving new hope to people affected by a wide range of autoimmune and degenerative illnesses," said Alexander. "StemGenex Medical Group is proud to offer the highest quality of care and to potentially help those with unmet clinical needs improve their quality of life."
ABOUT StemGenex Medical Group
StemGenex Medical Group is committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells. StemGenex provides stem cell therapy options for individuals suffering with inflammatory and degenerative illnesses. Committed to the science and innovation of stem cell treatment, StemGenex sponsors five clinical outcome studies registered with the National Institutes of Health (NIH) for Multiple Sclerosis, Parkinson's Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease (COPD) and Osteoarthritis. These have been established to formally document and evaluate the quality of life changes in individuals following adipose-derived stem cell treatment.
Contact: Jamie Schubert, Director of Media & Community Relations
jschubert@StemGenex.com, (858) 242-4243
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stem-cell-therapy-becomes-law-in-texas-300472809.html
SOURCE StemGenex Medical Group
